Research progress on exosome miRNA in diagnosis, treatment and prognosis of glioma

doi:10.3877/cma.j.issn.2095-123X.2021.06.011

Abstract

Abstract:

Glioma is one of the most common primary intracranial tumors, which is the most prominent invasive brain tumor derived from neuroectodermal glia. Exosomes are discoid vesicles with a diameter of 30-150 nm secreted by cells through exocytosis. Almost all types of cells secrete exosomes, which are widely present in blood, urine, saliva, cerebrospinal fluid and other extracellular fluids. Exosomes include proteins, lipids, microRNA (miRNA), messenger RNA and DNA. Only miRNA has low immunogenicity, low toxicity and blood flow stability. Therefore, it has become a promising therapeutic and diagnostic tool because of its excellent ability to mediate intercellular communication, especially in the progression of brain tumors. At present, more and more miRNAs are found to be involved in the pathogenesis, progression, diagnosis, prognosis and treatment of the glioma. This review will introduce the role of exosome miRNA in the diagnosis, treatment and prognosis of glioma.

Key words: Glioma, Exosome, MicroRNA

Xiaoyu Zhao, Yandong Li, Hao Wu, Hai Fan, Mingyue Lyu, Yusheng Shen, Chengjun Sheng, Jia Zeng, Xuchao Wu, Guohua Zhu, Dangmurenjiafu Geng. Research progress on exosome miRNA in diagnosis, treatment and prognosis of glioma[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2021, 11(06): 370-374.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2021.06.011

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2021/V11/I06/370

Figures/Tables 1

References 50

[1]	徐勇明，王宏勤. MicroRNA调控胶质瘤替莫唑胺化疗耐药的研究进展[J]. 中华神经创伤外科电子杂志, 2016, 2(4): 241-244.
[2]	Tabibkhooei A, Izadpanahi M, Arab A, et al. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas[J]. Clin Neurol Neurosurg, 2020, 190: 105652.
[3]	Shi R, Wang PY, Li XY, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients[J]. Oncotarget, 2015, 6(29): 26971-26981.
[4]	Guo X, Qiu W, Wang J, et al. Glioma exosomes mediate the expansion and function of myeloid-derived suppressor cells through microRNA-29a/Hbp1 and microRNA-92a/Prkar1a pathways[J]. Int J Cancer, 2019, 144(12): 3111-3126.
[5]	Guo X, Qiu W, Liu Q, et al. Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways[J]. Oncogene, 2018, 37(31): 4239-4259.
[6]	Wang ZF, Liao F, Wu H, et al. Glioma stem cells-derived exosomal miR-26a promotes angiogenesis of microvessel endothelial cells in glioma[J]. J Exp Clin Cancer Res, 2019, 38(1): 201.
[7]	Cai Q, Zhu A, Gong L. Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1[J]. Bull Cancer, 2018, 105(7-8): 643-651.
[8]	Xu H, Zhao G, Zhang Y, et al. Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2[J]. Stem Cell Res Ther, 2019, 10(1): 381.
[9]	Yu L, Gui S, Liu Y, et al. Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2[J]. Aging (Albany NY), 2019, 11(15): 5300-5318.
[10]	Figueroa J, Phillips LM, Shahar T, et al. Exosomes from glioma-associated mesenchymal stem cells increase the tumorigenicity of glioma stem-like cells via transfer of miR-1587[J]. Cancer Res, 2017, 77(21): 5808-5819.
[11]	Yue X, Lan F, Xia T. Hypoxic glioma cell-secreted exosomal miR-301a activates wnt/β-catenin signaling and promotes radiation resistance by targeting TCEAL7[J]. Mol Ther, 2019, 27(11): 1939-1949.
[12]	Yin J, Zeng A, Zhang Z, et al. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma[J]. EBioMedicine, 2019, 42: 238-251.
[13]	Li Q, Wang AY, Xu QG, et al. In-vitro inhibitory effect of EGFL7-RNAi on endothelial angiogenesis in glioma[J]. Int J Clin Exp Pathol, 2015, 8(10): 12234-12242.
[14]	Molinaro AM, Taylor JW, Wiencke JK, et al. Genetic and molecular epidemiology of adult diffuse glioma[J]. Nat Rev Neurol, 2019, 15(7): 405-417.
[15]	Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996.
[16]	Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment[J]. Pharmacol Ther, 2015, 152: 63-82.
[17]	H Rashed M, Bayraktar E, K Helal G, et al. Exosomes: from garbage bins to promising therapeutic targets[J]. Int J Mol Sci, 2017, 18(3): 538.
[18]	Saadatpour L, Fadaee E, Fadaei S, et al. Glioblastoma: exosome and microRNA as novel diagnosis biomarkers[J]. Cancer Gene Ther, 2016, 23(12): 415-418.
[19]	Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers[J]. Nat Cell Biol, 2008, 10(12): 1470-1476.
[20]	Hallal S, Russell BP, Wei H, et al. Extracellular vesicles from neurosurgical aspirates identifies chaperonin containing TCP1 subunit 6A as a potential glioblastoma biomarker with prognostic significance[J]. Proteomics, 2019, 19(1-2): e1800157.
[21]	Williams N. Solvents in the workplace[J]. Occup Health (Lond), 1995, 47(5): 169-170.
[22]	Li CC, Eaton SA, Young PE, et al. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells[J]. RNA Biol, 2013, 10(8): 1333-1344.
[23]	Chen X, Yang F, Zhang T, et al. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma[J]. J Exp Clin Cancer Res, 2019, 38(1): 99.
[24]	Santangelo A, Imbrucè P, Gardenghi B, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker[J]. J Neurooncol, 2018, 136(1): 51-62.
[25]	Henriksen M, Johnsen KB, Olesen P, et al. MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme[J]. Neuromolecular Med, 2014, 16(3): 565-577.
[26]	Sun X, Ma X, Wang J, et al. Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal[J]. Oncotarget, 2017, 8(22): 36137-36148.
[27]	Lang FM, Hossain A, Gumin J, et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas[J]. Neuro Oncol, 2018, 20(3): 380-390.
[28]	van der Vos KE, Abels ER, Zhang X, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain[J]. Neuro Oncol, 2016, 18(1): 58-69.
[29]	Monteforte A, Lam B, Sherman MB, et al. Glioblastoma exosomes for therapeutic angiogenesis in peripheral ischemia[J]. Tissue Eng Part A, 2017, 23(21-22): 1251-1261.
[30]	Akers JC, Ramakrishnan V, Kim R, et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients[J]. J Neurooncol, 2015, 123(2): 205-216.
[31]	Fareh M, Almairac F, Turchi L, et al. Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth[J]. Cell Death Dis, 2017, 8(3): e2713.
[32]	Tüzesi Á, Kling T, Wenger A, et al. Pediatric brain tumor cells release exosomes with a miRNA repertoire that differs from exosomes secreted by normal cells[J]. Oncotarget, 2017, 8(52): 90164-90175.
[33]	Deng SZ, Lai MF, Li YP, et al. Human marrow stromal cells secrete microRNA-375-containing exosomes to regulate glioma progression[J]. Cancer Gene Ther, 2020, 27(3-4): 203-215.
[34]	Shao N, Xue L, Wang R, et al. miR-454-3p is an exosomal biomarker and functions as a tumor suppressor in glioma[J]. Mol Cancer Ther, 2019, 18(2): 459-469.
[35]	Qian M, Wang S, Guo X, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways[J]. Oncogene, 2020, 39(2): 428-442.
[36]	Katakowski M, Buller B, Zheng X, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth[J]. Cancer Lett, 2013, 335(1): 201-204.
[37]	Sharif S, Ghahremani MH, Soleimani M. Delivery of exogenous miR-124 to glioblastoma multiform cells by Wharton’s Jelly mesenchymal stem cells decreases cell proliferation and migration, and confers chemosensitivity[J]. Stem Cell Rev Rep, 2018, 14(2): 236-246.
[38]	Lan F, Qing Q, Pan Q, et al. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma[J]. Cell Oncol (Dordr), 2018, 41(1): 25-33.
[39]	Zeng A, Wei Z, Yan W, et al. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma[J]. Cancer Lett, 2018, 436: 10-21.
[40]	Yang C, Wang C, Chen X, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas[J]. Int J Cancer, 2013, 132(1): 116-127.
[41]	Ansari KI, Ogawa D, Rooj AK, et al. Glucose-based regulation of miR-451/AMPK signaling depends on the OCT1 transcription factor[J]. Cell Rep, 2015, 11(6): 902-909.
[42]	Kim R, Lee S, Lee J, et al. Exosomes derived from microRNA-584 transfected mesenchymal stem cells: novel alternative therapeutic vehicles for cancer therapy[J]. BMB Rep, 2018, 51(8): 406-411.
[43]	Wang J, Che F, Zhang J, et al. Diagnostic and prognostic potential of serum cell-free microRNA-214 in glioma[J]. World Neurosurg, 2019, 125: e1217-e1225.
[44]	Khan AR, Yang X, Fu M, et al. Recent progress of drug nanoformulations targeting to brain[J]. J Control Release, 2018, 291: 37-64.
[45]	Bronisz A, Wang Y, Nowicki MO, et al. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1[J]. Cancer Res, 2014, 74(3): 738-750.
[46]	Munoz JL, Bliss SA, Greco SJ, et al. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity[J]. Mol Ther Nucleic Acids, 2013, 2(10): e126.
[47]	Ghaemmaghami AB, Mahjoubin-Tehran M, Movahedpour A, et al. Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis[J]. Cell Commun Signal, 2020, 18(1): 120.
[48]	Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development[J]. PLoS One, 2013, 8(10): e78115.
[49]	Li Z, Ye L, Wang L, et al. Identification of miRNA signatures in serum exosomes as a potential biomarker after radiotherapy treatment in glioma patients[J]. Ann Diagn Pathol, 2020, 44: 151436.
[50]	Lan F, Yue X, Xia T. Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma[J]. Oncol Lett, 2020, 19(3): 1967-1974.

microRNA	目的基因	表达状态	诊断意义	生物作用	预后意义	参考文献
miR-29a	Hbp1	上调	否	调节免疫抑制微环境	否	[4]
miR-92a	Prkar1a	上调	否	调节免疫抑制微环境	否	[4]
miR-10a	RORA,PTEN	上调	是	调节免疫抑制微环境	是	[5]
miR-21	RORA、PTEN、VEGF、c-Myc	上调	是	调节免疫抑制微环境,促进增殖和免疫抑制	是	[5,24,26,28,30,39]
miR-26a	PTEN	上调	否	促进血管生成	否	[6]
miR-148a	CADM1	下调	是	促进增殖和转移	否	[7]
miR-133b	EZH2	下调	否	抑制增殖、侵袭和迁移	否	[8]
miR-199a	AGAP2	下调	否	抑制增殖、侵袭，增强化学治疗敏感性	否	[9]
miR-1587	NCOR1	下调	否	增加致瘤性	否	[10]
miR-301a	TCEAL7	上调	是	提高放射治疗抗性	是	[11,40]
miR-1238	CAV1	上调	否	促进增殖、迁移和替莫唑胺抗性	否	[12]
miR-9	COL18A1、THBS2、PTCH1、PHD3	上调	否	增加血管生成	否	[23]
miR-222		上调	是	-	是	[24]
miR-124a	FOXA2	上调	否	使胶质瘤细胞活力和克隆原性显著降低	否	[27]
miR-451	c-Myc	上调	是	促进增殖和免疫抑制	是	[28,41]
miR-221		上调	否	促进增殖、迁移和替莫唑胺抗性	否	[29,40]
miR-103		上调	是	-	是	[30]
miR-24		上调	是	-	是	[30]
miR-125		上调	是	-	是	[30]
miR-1290		上调	否	调节免疫抑制微环境	否	[32]
miR-1246		上调	否	调节免疫抑制微环境	否	[32]
miR-375	SLC31A1	下调	否	抑制神经胶质瘤进展	否	[33]
miR-454-3p	ATG12	下调	是	-	否	[34]
miR-146b	EGFR、NF-κB	下调	否	减少胶质瘤在体内的生长	否	[36]
miR-124	CDK6	下调	否	抑制胶质瘤增殖，迁移，并具有化学治疗敏感性	否	[37]
miR-151a	XRCC4	上调	是	增强对替莫唑胺的化学敏感性	是	[39]
miR-584-5p	CYP2J2	上调	否	抑制胶质瘤细胞增殖转移	否	[42]
miR-214	PCBP2	上调	是	抑制胶质瘤细胞增殖生长	是	[43]

microRNA	目的基因	表达状态	诊断意义	生物作用	预后意义	参考文献
miR-29a	Hbp1	上调	否	调节免疫抑制微环境	否	[4]
miR-92a	Prkar1a	上调	否	调节免疫抑制微环境	否	[4]
miR-10a	RORA,PTEN	上调	是	调节免疫抑制微环境	是	[5]
miR-21	RORA、PTEN、VEGF、c-Myc	上调	是	调节免疫抑制微环境,促进增殖和免疫抑制	是	[5,24,26,28,30,39]
miR-26a	PTEN	上调	否	促进血管生成	否	[6]
miR-148a	CADM1	下调	是	促进增殖和转移	否	[7]
miR-133b	EZH2	下调	否	抑制增殖、侵袭和迁移	否	[8]
miR-199a	AGAP2	下调	否	抑制增殖、侵袭，增强化学治疗敏感性	否	[9]
miR-1587	NCOR1	下调	否	增加致瘤性	否	[10]
miR-301a	TCEAL7	上调	是	提高放射治疗抗性	是	[11,40]
miR-1238	CAV1	上调	否	促进增殖、迁移和替莫唑胺抗性	否	[12]
miR-9	COL18A1、THBS2、PTCH1、PHD3	上调	否	增加血管生成	否	[23]
miR-222		上调	是	-	是	[24]
miR-124a	FOXA2	上调	否	使胶质瘤细胞活力和克隆原性显著降低	否	[27]
miR-451	c-Myc	上调	是	促进增殖和免疫抑制	是	[28,41]
miR-221		上调	否	促进增殖、迁移和替莫唑胺抗性	否	[29,40]
miR-103		上调	是	-	是	[30]
miR-24		上调	是	-	是	[30]
miR-125		上调	是	-	是	[30]
miR-1290		上调	否	调节免疫抑制微环境	否	[32]
miR-1246		上调	否	调节免疫抑制微环境	否	[32]
miR-375	SLC31A1	下调	否	抑制神经胶质瘤进展	否	[33]
miR-454-3p	ATG12	下调	是	-	否	[34]
miR-146b	EGFR、NF-κB	下调	否	减少胶质瘤在体内的生长	否	[36]
miR-124	CDK6	下调	否	抑制胶质瘤增殖，迁移，并具有化学治疗敏感性	否	[37]
miR-151a	XRCC4	上调	是	增强对替莫唑胺的化学敏感性	是	[39]
miR-584-5p	CYP2J2	上调	否	抑制胶质瘤细胞增殖转移	否	[42]
miR-214	PCBP2	上调	是	抑制胶质瘤细胞增殖生长	是	[43]

Please choose a citation manager

Content to export